Logo image of CERS

CERUS CORP (CERS) Stock Fundamental Analysis

USA - NASDAQ:CERS - US1570851014 - Common Stock

1.46 USD
+0.16 (+12.31%)
Last: 9/19/2025, 8:00:00 PM
1.4612 USD
+0 (+0.08%)
After Hours: 9/19/2025, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, CERS scores 3 out of 10 in our fundamental rating. CERS was compared to 191 industry peers in the Health Care Equipment & Supplies industry. CERS has a bad profitability rating. Also its financial health evaluation is rather negative. CERS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CERS had negative earnings in the past year.
CERS had a positive operating cash flow in the past year.
CERS had negative earnings in each of the past 5 years.
CERS had negative operating cash flow in 4 of the past 5 years.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

CERS has a Return On Assets of -8.86%. This is in the better half of the industry: CERS outperforms 63.35% of its industry peers.
With a Return On Equity value of -34.06%, CERS perfoms like the industry average, outperforming 54.45% of the companies in the same industry.
Industry RankSector Rank
ROA -8.86%
ROE -34.06%
ROIC N/A
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

CERS has a better Gross Margin (60.94%) than 61.78% of its industry peers.
CERS's Gross Margin has been stable in the last couple of years.
CERS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CERS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CERS has been increased compared to 5 years ago.
The debt/assets ratio for CERS is higher compared to a year ago.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CERS has an Altman-Z score of -4.83. This is a bad value and indicates that CERS is not financially healthy and even has some risk of bankruptcy.
CERS's Altman-Z score of -4.83 is on the low side compared to the rest of the industry. CERS is outperformed by 68.59% of its industry peers.
CERS has a debt to FCF ratio of 24.80. This is a negative value and a sign of low solvency as CERS would need 24.80 years to pay back of all of its debts.
CERS's Debt to FCF ratio of 24.80 is fine compared to the rest of the industry. CERS outperforms 70.68% of its industry peers.
A Debt/Equity ratio of 1.02 is on the high side and indicates that CERS has dependencies on debt financing.
With a Debt to Equity ratio value of 1.02, CERS is not doing good in the industry: 78.01% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF 24.8
Altman-Z -4.83
ROIC/WACCN/A
WACC8.82%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

CERS has a Current Ratio of 2.00. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
CERS's Current ratio of 2.00 is on the low side compared to the rest of the industry. CERS is outperformed by 63.35% of its industry peers.
A Quick Ratio of 1.35 indicates that CERS should not have too much problems paying its short term obligations.
CERS has a Quick ratio of 1.35. This is in the lower half of the industry: CERS underperforms 62.83% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 1.35
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.67% over the past year.
Looking at the last year, CERS shows a quite strong growth in Revenue. The Revenue has grown by 11.25% in the last year.
The Revenue has been growing by 16.50% on average over the past years. This is quite good.
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)11.25%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%16.34%

3.2 Future

The Earnings Per Share is expected to grow by 28.85% on average over the next years. This is a very strong growth
CERS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.35% yearly.
EPS Next Y-5.09%
EPS Next 2Y22.7%
EPS Next 3Y28.85%
EPS Next 5YN/A
Revenue Next Year21.32%
Revenue Next 2Y15.16%
Revenue Next 3Y14.35%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CERS is valued a bit cheaper than the industry average as 72.25% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 81.77
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

A more expensive valuation may be justified as CERS's earnings are expected to grow with 28.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.7%
EPS Next 3Y28.85%

More info and screens

0

5. Dividend

5.1 Amount

CERS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERUS CORP

NASDAQ:CERS (9/19/2025, 8:00:00 PM)

After market: 1.4612 +0 (+0.08%)

1.46

+0.16 (+12.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)10-28 2025-10-28/amc
Inst Owners73.45%
Inst Owner Change-3.19%
Ins Owners2.97%
Ins Owner Change1.65%
Market Cap279.88M
Analysts80
Price Target4.76 (226.03%)
Short Float %3.78%
Short Ratio6.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.16%
Min EPS beat(2)-6.95%
Max EPS beat(2)6.63%
EPS beat(4)3
Avg EPS beat(4)12.58%
Min EPS beat(4)-6.95%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)21.86%
EPS beat(12)7
Avg EPS beat(12)8.29%
EPS beat(16)11
Avg EPS beat(16)13.28%
Revenue beat(2)0
Avg Revenue beat(2)-10%
Min Revenue beat(2)-14.57%
Max Revenue beat(2)-5.44%
Revenue beat(4)1
Avg Revenue beat(4)-5.47%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-6.36%
Revenue beat(12)3
Avg Revenue beat(12)-5.39%
Revenue beat(16)7
Avg Revenue beat(16)-1.44%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-10%
EPS NQ rev (3m)-83.33%
EPS NY rev (1m)-7.93%
EPS NY rev (3m)12.82%
Revenue NQ rev (1m)-1.79%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)-2.34%
Revenue NY rev (3m)-2.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.29
P/FCF 81.77
P/OCF 49.02
P/B 5.05
P/tB 5.17
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)0.02
FCFY1.22%
OCF(TTM)0.03
OCFY2.04%
SpS1.13
BVpS0.29
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.86%
ROE -34.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.94%
FCFM 1.58%
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score5
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF 24.8
Debt/EBITDA N/A
Cap/Depr 163.87%
Cap/Sales 1.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 1.35
Altman-Z -4.83
F-Score5
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-5.09%
EPS Next 2Y22.7%
EPS Next 3Y28.85%
EPS Next 5YN/A
Revenue 1Y (TTM)11.25%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%16.34%
Revenue Next Year21.32%
Revenue Next 2Y15.16%
Revenue Next 3Y14.35%
Revenue Next 5YN/A
EBIT growth 1Y19.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year170.67%
EBIT Next 3Y60.42%
EBIT Next 5YN/A
FCF growth 1Y113.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y126.78%
OCF growth 3YN/A
OCF growth 5YN/A